Abstract
Pharmaceutical nanoparticles (NPs) carrying molecular payloads are used for medical purposes such as diagnosis and medical treatment. Currently, the research process of discovering a new applicative candidate for efficient clinical treatment is a time- and resource-consuming process due to the uncertainty of how NP behaves which requires a large number of experiments to study the properties of NPs-based drugs for clinical usage. In silico experiments are known to be powerful tools for studying biological and clinical systems and evaluating a drug’s efficiency, which can significantly reduce the number of in vivo experiments required. To this extent, in this study, we present a novel spatio-temporal pharmacokinetics-pharmacodynamics (PKPD) model of NPs based drugs. The proposed model takes into consideration the blood flow in the cardiovascular system as well as PKPD dynamics taking place during the drug’s flow and in the target sites. We show that the proposed model has a better fidelity compared to previous models on five in vivo experiments with 13 different NPs, done on mice.
Competing Interest Statement
The authors have declared no competing interest.
